EGFR and non-small cell lung carcinoma: As the genetic heterogeneity of lung tumors is responsible for the resistance or sensitivity to therapeutic drugs, EPP, which exerts general anticancer effects in cells with different EGFR mutations, could be beneficial for managing NSCLC [9,10].